Industry news that matters to you.  Learn more

Computable Genomix Secures Investment for the Development of Genetic Biomarker Tests

Reading time: < 1 minute

Memphis-based Computable Genomix announced this week that it has secured an investment from venture capital firm Innova Memphis to pilot a novel process for developing genetic biomarker tests. Leveraging its next-generation computational discovery capability, the company is developing highly targeted genetic biomarker tests for clinical researchers.

Brad Silver, chief executive officer of Computable Genomix, said:

Current approaches to genetic biomarker development require clinical researchers to work with thousands of patient samples and sift through millions of possibilities to pinpoint a handful of potential biomarkers for further evaluation. Using Computable’s very targeted tests, clinical researchers need fewer patient samples to assess a small number of high-value biomarkers. The end result is savings of time and money.

Financial details of the investment were not disclosed.

Source: Business Wire